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Background. Norovirus places a substantial burden on healthcare systems, arising from infected patients, disease outbreaks, 
beds kept unoccupied for infection control, and staff absences due to infection. In settings with high rates of bed occupancy, oppor-
tunity costs arise from patients who cannot be admitted due to beds being unavailable. With several treatments and vaccines against 
norovirus in development, quantifying the expected economic burden is timely.
Methods. The number of inpatients with norovirus-associated gastroenteritis in England was modeled using infectious and 
noninfectious gastrointestinal Hospital Episode Statistics codes and laboratory reports of gastrointestinal pathogens collected at 
Public Health England. The excess length of stay from norovirus was estimated with a multistate model and local outbreak data. 
Unoccupied bed-days and staff absences were estimated from national outbreak surveillance. The burden was valued convention-
ally using accounting expenditures and wages, which we contrasted to the opportunity costs from forgone patients using a novel 
methodology.
Results. Between July 2013 and June 2016, 17.7% (95% confidence interval [CI], 15.6%‒21.6%) of primary and 23.8% (95% CI, 
20.6%‒29.9%) of secondary gastrointestinal diagnoses were norovirus attributable. Annually, the estimated median 290 000 (inter-
quartile range, 282 000‒297 000) occupied and unoccupied bed-days used for norovirus displaced 57 800 patients. Conventional 
costs for the National Health Service reached £107.6 million; the economic burden approximated to £297.7 million and a loss of 
6300 quality-adjusted life-years annually.
Conclusions. In England, norovirus is now the second-largest contributor of the gastrointestinal hospital burden. With the pro-
jected impact being greater than previously estimated, improved capture of relevant opportunity costs seems imperative for diseases 
such as norovirus.
Keywords. burden of disease; opportunity costs; gastroenteritis; norovirus; outbreaks.
Norovirus has been associated with almost one-fifth of cases 
of all-cause acute gastroenteritis worldwide [1], resulting in an 
estimated median of 698.8 million illnesses and 218 800 deaths 
annually across all ages [2]. Norovirus most commonly occurs in 
the community [2–4]. However, local hospital outbreaks of nor-
ovirus are highly disruptive and have significant economic costs 
internationally [5–8]. These outbreaks can lead to increased 
norovirus-specific infections that may reduce available beds 
within the hospital system through infected patients blocking 
space for new admissions, beds left unoccupied for reasons of 
infection control and to allow cleaning and decontamination 
after outbreaks, and staff absences due to infection [5, 9, 10].
The impact of norovirus on the hospital system prompted 
the introduction of the English Hospital Norovirus Outbreak 
Reporting System (HNORS) in 2009 [11], and in 2010 the 
National Health Service (NHS) England started monitoring 
the performance of all acute care hospitals during winter [12]. 
While both systems enable detection of hospital bed pressures 
and norovirus outbreaks, neither collects individual-patient 
data. Therefore, the data collected by such surveillance systems 
alone do not capture the full burden of norovirus. With several 
antiviral treatments and vaccine candidates in development [13, 
14], obtaining a comprehensive overview of the baseline burden 
of norovirus in hospitals is timely to inform policy makers and 
investment in control strategies.
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Moreover, as acute hospitals in many countries [15], includ-
ing England [16], face high occupancy rates of beds, patients 
who cannot be admitted due to beds being unavailable result in 
health and economic losses to the healthcare system. Costing 
the burden of hospital infections such as norovirus has previ-
ously only considered actual expenditures incurred from deal-
ing with an outbreak [5, 9], ignoring the wider health impact for 
other patients awaiting admission [17]. This is likely to under-
estimate the impact of norovirus on the healthcare systems and, 
consequently, any benefits from investing in novel vaccines, 
treatments, or infection control.
METHODS
Data Sources
Number of patients, bed-days lost, and staff absences during norovi-
rus outbreaks
Since 2009, hospitals have been encouraged to voluntarily 
report norovirus outbreaks (defined as ≥2 cases in a func-
tional care unit) to HNORS at http://bioinformatics.phe.org.
uk/noroOBK. Previously, the underreporting in this web-based 
surveillance system was estimated at about 20% [11]. The num-
bers of patients, staff absences, and lost bed-days due to norovi-
rus were obtained for all outbreaks declared between July 2009 
and by week 27 of  June 2016.
Hospital Statistics for Gastrointestinal Illnesses
The observed number of inpatients with primary and second-
ary gastrointestinal disease diagnoses and the bed-days occu-
pied by the inpatients with primary diagnoses were obtained 
for July 2009 to June 2016 from the Hospital Episode Statistics 
database, which holds all records of NHS hospitalizations in 
England [18]. Primary diagnoses describe the main reason for 
hospitalization, whereas secondary diagnoses describe comor-
bidities of patients treated for another primary medical reason. 
Cases with all-cause gastroenteritis were identified using the 
International Classification of Diseases, Tenth Revision, and the 
diagnosis codes of infectious as well as noninfectious intestinal 
diseases A00‒A09, K52.8, and K52.9 [19, 20].
Laboratory Data of Gastrointestinal Pathogens
The weekly number of laboratory reports submitted to Public 
Health England for surveillance purposes by microbiology 
laboratories across England were obtained for July 2009 to 
June 2016 for the following gastrointestinal pathogens: adeno-
virus (enteric infections–associated group F serotypes 40 and 
41), astrovirus, Campylobacter, Cryptosporidium, Giardia, 
norovirus, rotavirus, nontyphoidal Salmonella (ie, exclud-
ing Salmonella Typhi and Salmonella Paratyphi), and Shigella. 
Listeria cases were obtained from national surveillance of lister-
iosis in England and Wales. In a separate analysis, cases of Shiga 
toxin–producing Escherichia coli (STEC) were also included as 
this was only available up to December 2015.
Patient-Level Data of Norovirus Infections From a Local Hospital
This study obtained individual-level data collected during a 
norovirus outbreak on 4 wards of a large teaching hospital in 
London in 2015. Routinely collected data were also obtained on 
age, sex, dates of admission and discharge, primary and up to 
11 secondary diagnosis codes, norovirus sample collection date, 
and discharge status for all patients admitted to the same wards 
and days for 2015 with a 2-year look-back. Cases were identi-
fied based on the primary diagnosis code, the first positive nor-
ovirus genogroup II (GII) infection sample during the hospital 
stay, and, for the outbreak in 2015, symptom onset.
Number of Bed-Days Kept Unoccupied due to Norovirus-Like 
Symptoms During Winters
It is mandatory for acute care hospitals to report the number 
of bed-days kept unoccupied due to diarrhea and vomiting/
norovirus-like symptoms during winters to NHS England since 
2010. We obtained these data for winters 2010–2011 to 2015–
2016 [12].
For more details on data sources and information retrieval, 
see Supplementary Material A.
Statistical Analysis to Estimate the Burden of Disease
Linear Regression Models
We used multiple linear regression models to attribute norovirus 
to patients with gastroenteritis by using the laboratory reports 
of relevant gastrointestinal pathogens as explanatory variables 
and inpatients diagnosed with gastrointestinal illnesses as the 
response variable (Supplementary Material B). In a separate 
analysis, we limited the data up to December 2015 to be able to 
include STEC.
Multistate Models
We estimated the excess length of hospital stays due to norovi-
rus with a multistate model that consisted of 4 mutually exclu-
sive states: (1) admitted (uninfected); (2) infected/diseased; 
(3) discharged alive; and (4) in-hospital death (Supplementary 
Material C). After admission (1), all inpatients were dis-
charged alive (3) or died (4); becoming infected/diseased (2) 
was optional before being discharged alive (3) or dead (4). The 
model used the empirical transition matrix of inpatients from 
the local patient-level hospital data. We ran the model sepa-
rately with all norovirus cases, and for cases with a secondary 
norovirus diagnosis.
Adjustments for Potential Underreporting of Unoccupied Bed-Days 
and Staff Absences
We estimated the number of bed-days kept unoccupied during 
norovirus outbreaks based on the national surveillance data. 
As these data are voluntarily reported, there could be underre-
porting of outbreaks, or lost bed-days. We accounted for under-
reporting of lost bed-days during an outbreak (and implicitly 
underreported outbreaks), using the recorded number of 
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unoccupied bed-days mandatorily reported to NHS England 
(Supplementary Material D). We adjusted the reported num-
ber of staff absences by the estimated underreporting of out-
breaks [11] and by using a previous norovirus outbreak study in 
England [5] (Supplementary Material E).
All analyses were performed in R software version 3.3.1 
[21]. For the multistate model, we used the R-packages mvna 
to model the hazards between states [22] and etm to estimate 
the excess length of stay [23]. We report the median and inter-
quartile range (IQR) across seasons; for results per season, see 
Supplementary Material A and H.
Costing the Burden of Disease
Costing Convention
For inpatients with norovirus-associated gastroenteritis and 
bed-days kept unoccupied, we calculated expenditures con-
ventionally using national administrative accounting data for 
2015–2016 [24] (Supplementary Material F). Staff absences due 
to infection were costed based on the national average wage of 
nurses in 2015–2016 [25]. To indicate financial (monetary) sav-
ings on nonfixed hospital resources if all norovirus cases were 
to be averted [26], we assumed a proportion of variable costs of 
15% of the total healthcare expenditure on norovirus, including 
staff absence costs [27].
Opportunity Costing From Forgone Admissions
Given the high occupancy rates of hospital beds in England [16], 
opportunity costs arise from alternative patients who cannot be 
admitted due to beds being unavailable [17]. The forgone health 
gain from hospital treatment was estimated in terms of quali-
ty-adjusted life years (QALYs), using our local patient sample 
(Supplementary Material G). QALY gains beyond 1  year were 
discounted at 3.5%, and we considered £20 000 as monetary 
value assigned to each QALY gained [28] to calculate net bene-
fits. In case a higher net benefit was achievable with the alterna-
tive patients forgone, the sum of the incurred expenditure and 
the forgone net benefit approximate to opportunity costs [17].
Sensitivity Analysis
We performed multivariate sensitivity analyses on all input 
parameters (Supplementary Material F).
Ethics Approval
Ethical approvals for this study were received from the Ethics 
Committee of the London School of Hygiene and Tropical Medicine 
(reference number 11824) and the North West–Liverpool Central 
Research Ethics Committee (reference 14/NW/1433).
RESULTS
Description of the Data
During July 2009 to June 2016, there were a total of 8140 nor-
ovirus outbreaks voluntarily reported to HNORS, involving 
77 800 patients, 20 100 staff recorded absent, and 99 200 lost 
bed-days (Supplementary Material A). Of the 658 100 enteric 
laboratory reports in total to national surveillance, the 3 most 
frequently reported pathogens were Campylobacter with 60.7%, 
rotavirus with 10.8%, and norovirus with 8.6%. Concurrently, 
Hospital Episode Statistics recorded across all ages 1 621 000 
primary all-cause gastrointestinal diagnoses vs 1 672 000 
patients with secondary all-cause gastrointestinal diagnoses 
(including 13.1% day cases). The number of primary gastro-
intestinal diagnoses stabilized after July 2013, whereas the 
number of patients with secondary gastrointestinal diagnoses 
kept increasing (Figure 1), driven by infections in adults and 
the elderly (Supplementary Material A). Based on the data of 
NHS England, an estimated 142 100‒186 000 unoccupied acute 
care hospital bed-days were closed (ie, unavailable) due to nor-
ovirus-like symptoms during the 6 winters from 2010–2011 to 
2015–2016.
The analysis of the local patient-level sample comprised 2509 
individual hospital stays, including 33 associated with norovi-
rus and another 11 with primary infectious intestinal diagnoses 
(Table 1).
Statistical Analysis to Estimate the Burden of Disease
Linear Regression Model Results
The regression models with the highest goodness-of-fit showed 
a significantly increasing proportion of primary and all diag-
noses being attributable to norovirus after July 2013, whereas 
the proportions of rotavirus-attributable primary and all diag-
noses decreased significantly after July 2013 (Supplementary 
Material B and Figure 2). Due to the heterogeneity across the 
7 seasons, we continue reporting results for July 2013 to June 
2016. Moreover, the significant reduction in rotavirus diag-
noses was driven by 0- to 4-year-olds, while the significant 
increase for norovirus was driven by patients aged 0–64 years 
(Supplementary Material B). Given that confidence intervals 
(CIs) for norovirus overlapped across age groups, we continue 
reporting nonstratified results.
Between July 2013 and June 2016, the best-fitting regression 
models attributed 17.7% of primary gastrointestinal diagnoses 
(95% CI, 15.6%‒21.6%) and 23.8% (95% CI, 20.6%‒29.9%) of 
secondary gastrointestinal diagnoses to norovirus (Figure  1), 
leading to a median estimate of 40 800 (IQR, 40 500‒41 400) 
norovirus-associated cases with primary and 61 500 (IQR, 
58 700‒62 500) with secondary diagnoses annually. Results 
were slightly lower when limiting the data to December 2015 to 
include STEC (Supplementary Material B).
Multistate Model Results
The mean excess length of hospital stay due to norovirus was 
estimated at 3.3 days (95% CI, .2‒6.5 days). Patients with nor-
ovirus infection and a secondary gastrointestinal diagnosis 
stayed an excess 4.0 days (95% CI, .4‒7.6 days).
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Bed-Days Kept Unoccupied for Infection Control
A median of 19.7%‒26.3% of bed-days lost in outbreaks volun-
tarily reported to HNORS by acute care hospitals during the 
winters of 2013–2014 to 2015–2016 matched with those man-
datorily recorded by NHS England (Supplementary Material D).
Total Number of Bed-Days Used for Norovirus
Annually, at least 290 000 (IQR, 282 000‒297 000) occupied and 
unoccupied bed-days were norovirus attributable using conser-
vative estimates (Supplementary Material H), with 28% being 
used by inpatients with a primary diagnosis, 62% by secondary 
diagnoses, and 10% were beds that had been closed unoccupied.
Staff Absences due to Norovirus
An estimated median of 4200 (IQR, 3800‒5100) members of 
staff were absent during norovirus outbreaks annually between 
mid-2013 and mid-2016.
Costing the Burden of Disease
Direct Expenditures Incurred due to Norovirus
Norovirus-associated gastroenteritis incurred direct expendi-
tures of £107.6 million (IQR, £104.6‒£109.8 million) annually, 
of which £8.9 million (IQR,  £8.6‒£10.4 million) were lost on 
unoccupied bed-days. Staff absences due to infection incurred 
costs for the NHS of £1.3 million (IQR,  £1.2‒£1.6 million) 
annually. The 15% variable costs proportion indicates potential 
monetary savings from averting all norovirus cases equivalent 
to £16.1 million (IQR, £15.7‒£16.5 million).
Opportunity Costing
The 290 000 norovirus-associated bed-days could have been 
used for 57 800 (IQR, 56 400‒59 200) alternative nongastroen-
teritis patients, who would have been expected to gain 13 800 
(IQR, 13 500‒14 100) QALYs at a net monetary benefit of £190.1 
million (IQR, £185.5‒£194.7 million). From a health-maximiz-
ing perspective, the forgone nongastroenteritis patients were 
expected to have gained a higher net benefit than the norovirus 
cases (Supplementary Material H), with the value of the opportu-
nity costs approximating to £297.7 million (IQR, £290.1‒£304.5 
million) and losing an estimated 6300 QALYs (ie, 13 800 minus 
7500; see Supplementary Material H).
Sensitivity Analysis
Sensitivity analyses confirmed that the wide uncertainty 
range around the excess length of stay estimate was the most 
influential source of uncertainty for the burden estimation 
(Supplementary Material I).
For the estimation of the costs, the monetary value assigned to 
QALYs was the most influential parameter with a direct impact on 
the estimates of the economic costs (Supplementary Material I).
Figure 1. National hospital statistics for inpatients with infectious and noninfectious gastrointestinal (primary and secondary) diagnoses and laboratory-confirmed cases 
of norovirus in England, July 2009 to June 2016, visualizing norovirus-attributable proportions using linear regressions fitted to the data before and after July 2013. Reported 
values are the mean and 95% confidence interval (in brackets).
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DISCUSSION
This study quantified the hospital burden of norovirus-associ-
ated gastroenteritis for the NHS in England. It included for the 
first time the wider health impact that infectious diseases such 
as norovirus can have for other patients awaiting admission by 
reducing the beds and staff available to them [17].
Summary of Key Findings and Clinical Implications
Of all inpatients with primary or secondary all-cause gastroin-
testinal diagnoses in England between July 2013 and June 2016, 
18% (95% CI, 16%‒22%) and 24% (95% CI, 21%‒30%) were 
attributable to norovirus, respectively. While the general increase 
in patients diagnosed with gastrointestinal illnesses in England 
throughout this period seemed to be driven by secondary diag-
noses, the increase in norovirus-attributable inpatients identi-
fied after July 2013 appeared to be driven by primary diagnoses 
(less so by secondary diagnoses or outbreaks or coding varia-
tions; see Supplementary Material A). Discharging gastrointesti-
nal inpatients faster in recent years (Supplementary Material A) 
and enhanced hygiene and other infection control measures [10, 
29, 30], as well as a potentially increasing awareness [10], may all 
have contributed to fewer secondary norovirus-associated hos-
pital cases and norovirus outbreaks.
Our regression results also showed that norovirus is now the 
second-highest contributor of gastrointestinal hospital diagno-
ses, after Campylobacter. The proportional increase in the bur-
den of norovirus is largely driven by the reduction in rotavirus, 
which led to a reduced total number of laboratory-confirmed 
cases (see Supplementary Material A). Overall, the total num-
ber of bed-days tied up by norovirus-associated gastroenteri-
tis annually is equivalent to the entire daily NHS hospital bed 
capacity in England being unavailable for >2 days (ie, 290 000 / 
133 000 [16]). The bed-days lost to norovirus prevented admis-
sion of other patients, who are estimated to have the potential to 
gain twice as many QALYs from hospitalization as the norovi-
rus patients who displaced them. Therefore, our findings dem-
onstrate the wider impact of norovirus outbreaks on health. In 
addition, a combined £10.3 million was lost annually from bed-
days kept unoccupied and staff absences. With the prospect of 
several norovirus treatments and vaccines becoming available 
soon [13, 14], our estimates may serve as baseline for future 
analyses.
Comparison With Previous Work
Our estimate of 16% (95% CI, 15%–19%) of gastrointesti-
nal patients attributable to norovirus for July 2009 to June 
2013 is consistent with a previous estimate of 17% (95% CI, 
Table  1. Demographic Characteristics of the Local Sample of Patients From a Teaching Hospital in London, England, on the Wards Affected by the 
Norovirus Outbreak of 31 May–15 June 2015, and the Previous 2 Years
Variable
All Patients 
Analyzed (Cases 
and Controls)
Control Patients Without Gastroenteritis Cases With Norovirus
Patients With Acute 
Life-Threatening 
Conditionsa
Patients With 
Chronic Conditionsb
Patients Without 
Chronic or Life- 
Threatening 
Conditionsc
Suspected/Confirmed 
Norovirus Infectiond
Cases With Primary 
IID or Norovirus 
Diagnosise
Cases With 
Secondary 
Norovirus 
Diagnoses
Patients 2509 (88.0) 537 (18.8) 871 (30.5) 1057 (37.0) 33 (1.2) 17 (0.6) 27 (0.9)
Age, y, mean (SD) 59.2 (20.2) 75.1 (14.3) 61.7 (17.6) 48.7 (18.5) 70.8 (18.2) 56.9 (23.5) 73.5 (16.6)
Sex, female 1265 (50.4) 258 (48.0) 422 (48.4) 557 (52.7) 21 (63.6) 11 (64.7) 17 (63.0)
CCI score (>0) 1440 (57.4) 537 (100.0) 871 (100.0) 0 (0.0) 27 (81.8) 8 (47.1) 24 (88.9)
In-hospital mortality 54 (2.2) 21 (3.9) 26 (3.0) * * 0 (0.0) *
LOS, d, mean (range) 5.0 (0–43) 7.2 (0–43) 5.4 (0–43) 3.3 (0–40) 15.8 (3–43) 5.7 (0–25) 17.0 (3–43)
Excess LOS, d, mean 
(95% CI)f
NA NA NA NA 3.33 (.17–6.50) NA 3.95 (.35–7.55)
QALY gain (undis-
counted), mean  
(95% CI)g
0.179 (.0001–.386) 0.307 (.175–.377) 0.313 (.189–.403) 0.002 (.00005–.017) 0.227 (.003–.358) 0.102 (.0004–.295) 0.250 (.009–.365)
QALY gain (discounted), 
mean (95% CI)g
0.142 (.0001–.293) 0.260 (.162–.309) 0.239 (.175–.308) 0.002 (.00005–.017) 0.188 (.003–.295) 0.078 (.0004–.190) 0.211 (.009–.299)
Data are presented as No. (%) unless otherwise indicated. The asterisk (*) indicates a figure between 1 and 5, values suppressed to prevent possible identification of individuals [18].
Abbreviations: CCI, Charlson comorbidity index; CI, confidence interval; GII, norovirus genogroup II; IID, infectious intestinal disease; LOS, length of stay; NA, not applicable; PCR, poly-
merase chain reaction; QALY, quality-adjusted life-year; SD, standard deviation.
aMyocardial infarction, congestive heart failure, or cerebrovascular disease.
bCCI > 0 but not acutely life-threatening (ie, myocardial infarction, congestive heart failure, or cerebrovascular disease).
cCCI = 0, ie, no chronic or life-threatening conditions.
dSuspected infection (for the norovirus outbreak cluster in 2015) and all laboratory-confirmed norovirus GII infections; partly overlapping.
ePatients with a primary gastrointestinal diagnosis and laboratory-confirmed norovirus infection (n = 6) or without confirmed norovirus infection (n = 11). No excess LOS is presented here 
given that hospitalizations for a primary IID but without laboratory-confirmed norovirus diagnosis cannot necessarily be categorized as an excess stay.
fEstimated with the multistate model (Supplementary Material C).
gFor cases with secondary norovirus diagnoses, the QALYs gained were driven by the high level of comorbidities. If we approximated the gastroenteritis-related health gain by subtracting 
the QALY gain of control patients from the QALY gain of inpatients with secondary norovirus diagnoses, we derive 0.211 – 0.142 = 0.069 (ie, close to the gain of primary cases). For all cases, 
the activity-weighted mean (discounted) QALY gain amounted to (0.069 × 27 + 0.078 × 17) / 44 = 0.072 QALYs gained, ie, about half of the control patients who gained 0.142 QALYs (see 
Supplementary Table 4).
Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciy167/4909815
by London School of Hygiene & Tropical Medicine user
on 05 April 2018
6 • CID 2018:XX (XX XXXX) • Sandmann et al
15%‒19%) from a systematic review of studies published up 
to 2014 [1], irrespective of novel norovirus strain emergences. 
After July 2013, we estimated that this increases to 21% (95% 
CI, 19%‒25%), which is not attributable to the emergence of 
a novel norovirus strain, but appeared to be driven by statisti-
cally significantly higher proportions in children aged 0–4 and 
5–18 years and adults aged 19–64 years (Figure 2).
Previously, the costs attributable to unavailable bed-days due 
to norovirus-like symptoms for acute care hospitals were esti-
mated as £35‒£49 million in England each winter using the excess 
bed-day cost value for 2015–2016 [31]. Another study estimated 
the hospital costs of gastroenteritis outbreaks in England at £115 
million annually using a top-down approach and data from 
1994–1995 and 2002–2003 [5], which translates to costs from 
norovirus outbreaks of £96.9 million in 2016 value [32] when 
accounting for norovirus being present in only 63% of gastroen-
teritis outbreaks [5]. While we estimated higher expenditures of 
£107.6 million, the economic costs of £297.7 million (including 
hospitalizations forgone) are almost thrice as large.
Strengths and Limitations
This study is the first to combine individual-level data with 
national hospital surveillance and statistics to apply a novel 
method for estimating the opportunity costs of norovirus 
infections in hospital from patients who cannot be admit-
ted due to beds being unavailable. This novel methodology is 
generalizable to other settings, given high bed occupancy rates 
in other places besides England [15, 16]. Moreover, given the 
interest in the economic value of the bed-days that could not 
be used for alternative admissions, no actual cases may have 
always been delayed or canceled. Furthermore, the approach 
could be applied to community settings using, for example, 
general practitioner visits instead of hospitalizations [17]. The 
potential for these analytical approaches is likely to increase in 
the future given the increasing number of linkable data sources.
Our study here used the best available data sources for 
norovirus, which we adjusted for bias in reporting [11, 12]. 
Unadjusted HNORS data were not used directly due to under-
reporting of outbreaks, cases, and bed-days. Although our 
regression analysis assumed independence of observations, it is 
a well-described method to quantify the etiology of gastroen-
teritis [19, 20, 33] that captures correlations in weekly counts 
implicitly through the explanatory variables. Given the large 
sizes of the data used for the regression analysis, a linear model 
was chosen; however, results are also robust to a negative bino-
mial model (Supplementary Material B). The regression also 
accounted for potential miscoding of intestinal diagnoses [19, 
20], and we used a statistically rigorous method accounting for 
time-dependent biases [34–36] to estimate the excess length 
of stay. A  possible limitation is our use of the local data to 
model length of stay and the expected QALY gain from hospi-
tal treatment. Moreover, we took the previously estimated 20% 
Figure 2. Attributable fraction (%) of enteric pathogens on all-cause acute gastrointestinal primary and secondary diagnoses in hospitals in England, using linear regres-
sions fitted to the data of July 2009 to June 2013 vs July 2013 to June 2016. Estimated absolute numbers provided for information. Abbreviations: CI, confidence interval; 
FCE, finished consultant episode; NA, not applicable.
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underreporting of outbreaks as a conservative estimate; the 
actual number of outbreaks may be higher. Likewise, the actual 
number of bed-days lost unoccupied remains uncertain due to 
the voluntary reporting to HNORS, and is likely higher than 
we assumed conservatively here despite our efforts of matching 
the bed-days. Future research should consider larger norovirus 
samples through advanced individual-patient infection control 
during outbreaks and longer observation periods.
The need to differentiate inpatients by their primary and 
secondary norovirus diagnosis arose mainly in order to not 
bias the total number of bed-days used for norovirus system-
atically upward [34–36]. Therefore, we relied on records of 
intestinal illness episodes in hospital; if illnesses are incom-
pletely recorded, our burden estimate may be an underestimate. 
Moreover, clinical hospital diagnoses may not fully capture 
patients with asymptomatic carriage of norovirus [37], and 
secondary diagnosis codes may be less reliable due to potential 
variation in coding practices between hospitals [18]. Note that 
a secondary diagnosis does not necessarily imply a hospital-ac-
quired infection. From the economic perspective of this study, 
however, the source of infection (ie, hospital acquired or com-
munity acquired) is irrelevant for obtaining a comprehensive 
picture of the burden of norovirus in hospitalized patients.
While our local sample did not involve pediatric or elderly 
wards, these were included in the national sources. We also did 
not consider indirect costs from productivity losses nor the 
costs borne by the community (or in long-term care facilities), 
which would substantially increase costs [2, 3, 38].
Our results support the hypothesis that a norovirus vaccine 
may have the greatest impact when reaching adult and the eld-
erly populations, particularly those at risk of infection while 
staying in hospital (Figure  2 and Supplementary Material A). 
However, future research needs to investigate the most appro-
priate target groups to prevent transmission, such as adult inpa-
tients, staff, and children [39,40].
CONCLUSIONS
With bed pressures being a recurring public health concern, any 
analysis considering the impact of infectious diseases on hospi-
tal systems needs to include the opportunity costs from forgone 
alternative admissions. In England, norovirus has become the 
second-largest contributor of inpatient gastrointestinal illnesses 
in England since mid-2013. Norovirus-associated gastroenteri-
tis ties up the equivalent of more than twice the daily hospital 
bed stock in England, with a substantial economic and health 
impact for the NHS and patients.
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the posted materials are not copyedited and are the sole responsibility of 
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